Literature DB >> 32668370

Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson's disease: A systematic review and meta-analysis.

Minh Toan Chau1, Gabrielle Todd2, Robert Wilcox3, Marc Agzarian4, Eva Bezak5.   

Abstract

INTRODUCTION: There is currently no definitive diagnostic test for Parkinson's disease (PD) and the current diagnostic procedure primarily relies on clinical manifestations. A hypointense appearance of nigrosome-1 (or absence of the "swallow tail" sign) on magnetic resonance imaging (MRI) has been proposed as a biomarker for PD. This meta-analysis examined the diagnostic accuracy of the appearance of nigrosome-1 on Magnetic Resonance Imaging (MRI) in differentiating idiopathic PD patients from healthy adults.
METHODS: Databases (MEDLINE, Embase, Scopus) were searched from 2012 (first publication of nigrosome-1 MRI scans) up until September 2019. Two researchers independently screened all titles and abstracts to identify studies that met the inclusion criteria and extracted relevant articles in a uniform manner. Two authors independently extracted data and assessed the risk of bias using a customized QUADAS-2 tool. Pooled sensitivity and specificity were calculated using a hierarchical summary receiver operating characteristic approach, as were positive and negative likelihood ratios.
RESULTS: Nineteen studies containing a total of 1508 participants (903 idiopathic PD patients and 605 healthy controls) were included. The overall sensitivity and specificity were 0.94 (95%CI, 0.93-0.96) and 0.90 (95%CI, 0.88-0.92), respectively. The likelihood ratios for positive and negative test results were 9.72 (95%CI, 5.58-16.04) and 0.08 (95%CI, 0.05-0.12). The pooled area under the receiver operating characteristics curve (AUC) in the diagnosis of idiopathic PD was 0.98.
CONCLUSIONS: Visual assessment of the nigrosome-1 appearance, at 3 or 7T, yields excellent diagnostic accuracy for differentiating idiopathic PD from healthy adults.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Neuroimaging; Parkinson's disease; Parkinsonism

Year:  2020        PMID: 32668370     DOI: 10.1016/j.parkreldis.2020.07.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  3 in total

1.  Diagnostic performance of loss of nigral hyperintensity on susceptibility-weighted imaging in parkinsonism: an updated meta-analysis.

Authors:  Pyeong Hwa Kim; Da Hyun Lee; Chong Hyun Suh; Minjae Kim; Woo Hyun Shim; Sang Joon Kim
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

Review 2.  Neuroimaging at 7 Tesla: a pictorial narrative review.

Authors:  Tomohisa Okada; Koji Fujimoto; Yasutaka Fushimi; Thai Akasaka; Dinh H D Thuy; Atsushi Shima; Nobukatsu Sawamoto; Naoya Oishi; Zhilin Zhang; Takeshi Funaki; Yuji Nakamoto; Toshiya Murai; Susumu Miyamoto; Ryosuke Takahashi; Tadashi Isa
Journal:  Quant Imaging Med Surg       Date:  2022-06

3.  Direct delivery of an investigational cell therapy in patients with Parkinson's disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design.

Authors:  Jorge E Quintero; John T Slevin; Julie A Gurwell; Christopher J McLouth; Riham El Khouli; Monica J Chau; Zain Guduru; Greg A Gerhardt; Craig G van Horne
Journal:  BMJ Neurol Open       Date:  2022-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.